Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Jan Philipp Bewersdorf, Andriy Derkach, Amer M. Zeidan, Eytan M. Stein, Michael J. Mauro, Nikolai A. Podoltsev, Raajit Rampal

Blood (2024) 144 (Supplement 1): 6659.

https://doi.org/10.1182/blood-2024-194918

Published: 2024

Journal Articles

Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States

Kunal C Potnis, Satoko Ito, Kishan Patel, Rory M. Shallis, Nikolai A. Podoltsev, Tariq Kewan, Jessica M. Stempel, Lourdes Mendez, Scott F Huntington, Maximilian Stahl, Amer M. Zeidan, Jan Philipp Bewersdorf, George Goshua

Blood (2024) 144 (Supplement 1): 3644.

https://doi.org/10.1182/blood-2024-204312

Published: 2024

Journal Articles

Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

Blood (2024) 144 (Supplement 1): 736.

https://doi.org/10.1182/blood-2024-210370

Published: 2024

Journal Articles

Use of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database

Jessica M. Stempel, Rong Wang, Alfred I Lee, Xiaomei Ma, Nikolai A. Podoltsev

Blood (2024) 144 (Supplement 1): 2319.

https://doi.org/10.1182/blood-2024-202185

Published: 2024

Journal Articles

Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia

Abdulrahman Alhajahjeh, Kishan Patel, Rory M. Shallis, Nikolai A. Podoltsev, Tariq Kewan, Jessica M. Stempel, Lourdes Mendez, Scott F Huntington, Maximilian Stahl, Amer M. Zeidan, George Goshua, Jan Philipp Bewersdorf

Blood (2024) 144 (Supplement 1): 788.

https://doi.org/10.1182/blood-2024-201535

Published: 2024

Journal Articles

Educational Impact of Live and Online Enduring CME Activities Presented at the 65 th ASH Annual Meeting on Hematology/Oncology Specialists Evaluated Using Pre-/Post-Education Assessments

Michelle Arielle Worst, Heather P. Friedman, Sarah E. Bomba, Megan Whitney, Davecia Cameron, Deborah Middleton, Charlotte Warren, Haleh Kadkhoda, Nikolai A. Podoltsev

Blood (2024) 144 (Supplement 1): 2445.

https://doi.org/10.1182/blood-2024-208458

Published: 2024

Journal Articles

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Blood (2024) 144 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2024-200397

Published: 2024

Journal Articles

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Blood (2024) 144 (Supplement 1): 4211.

https://doi.org/10.1182/blood-2024-207143

Published: 2024

Journal Articles

Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia

Cameron J. Hunter, Jan Philipp Bewersdorf, Lourdes Mendez, Nikolai A. Podoltsev, Amer M. Zeidan, William Eighmy, Heidi Roeder, Maricar Malinis, Rory M. Shallis

Blood (2024) 144 (Supplement 1): 1480.

https://doi.org/10.1182/blood-2024-211250

Published: 2024

Journal Articles

Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab

Jan Philipp Bewersdorf, Vanessa Hasle, Rory M. Shallis, Ethan G. Thompson, Daniel Lopes De Menezes, Shelonitda Rose, Isaac W. Boss, Lourdes Mendez, Nikolai A. Podoltsev, Maximilian Stahl, Tariq Kewan, Stephanie Halene, Torsten Haferlach, Brian Fox, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 4585.

https://doi.org/10.1182/blood-2024-194929

Published: 2024

Journal Articles

Risk Factors and Predictors of Outcomes after Invasive Fungal Infection Among Patients with Acute Myeloid Leukemia

Cameron J. Hunter, Jan Philipp Bewersdorf, Lourdes Mendez, Nikolai A. Podoltsev, Amer M. Zeidan, William Eighmy, Heidi Roeder, Maricar Malinis, Rory M. Shallis

Blood (2024) 144 (Supplement 1): 4253.

https://doi.org/10.1182/blood-2024-211426

Published: 2024

Journal Articles

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Blood (2023) 142 (Supplement 1): 3181.

https://doi.org/10.1182/blood-2023-173441

Published: 2023

Journal Articles

State‐Level Acute Myeloid Leukemia Incidence and Mortality Trends and Association with Obesity in the United States

Lixin Kang, Xiaomei Ma, Nikolai A. Podoltsev, Jessica M. Stempel, Rong Wang

Blood (2023) 142 (Supplement 1): 5184.

https://doi.org/10.1182/blood-2023-186428

Published: 2023

Journal Articles

Feasibility, Safety and Predictors of Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia Discharged “Early” after Intensive Induction Therapy

Cameron Hunter, Wei Cheng, Stephanie Halene, Lourdes Mendez, Nikolai A. Podoltsev, Amer M. Zeidan, Lisa Barbarotta, Rory M. Shallis

Blood (2023) 142 (Supplement 1): 589.

https://doi.org/10.1182/blood-2023-182989

Published: 2023

Journal Articles

A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034)

Keri Maher, Raajit K. Rampal, Prithviraj Bose, Nikolai A. Podoltsev, Claire N Harrison, Junshik Hong, Xulong Wang, Kamal Chamoun, John Mascarenhas

Blood (2023) 142 (Supplement 1): 3209.

https://doi.org/10.1182/blood-2023-180695

Published: 2023

Journal Articles

Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United States

Jessica M. Stempel, Allison J. Li, Alexander B Pine, Valentina Restrepo, Jan Philipp Bewersdorf, Maximilian Stahl, Nikolai A. Podoltsev, Lourdes Mendez, Rory M. Shallis, Deepa Rangachari, Alfred I Lee, Laura C. Michaelis, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 2319.

https://doi.org/10.1182/blood-2023-187163

Published: 2023

Journal Articles

The Value and Success of Live Plus Online Enduring CME/CE on Hematology/Oncology Specialists' Ability to Care for Patients with Hematologic Disorders

Michelle A. Worst, Heather P. Friedman, Sarah E. Bomba, Megan Whitney, Deborah Middleton, Emily Mikhael, Haleh Kadkhoda, Cong Zhang, Nikolai A. Podoltsev

Blood (2023) 142 (Supplement 1): 7282.

https://doi.org/10.1182/blood-2023-180360

Published: 2023

Journal Articles

Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 Trial

Rory M. Shallis, Ondrej Blaha, Stephanie Halene, Lourdes Mendez, Nikolai A. Podoltsev, Anne Caldwell, Jan Philipp Bewersdorf, Richard F. Little, Richard Piekarz, Mrinal M. Patnaik, Steven D. Gore, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2023-182814

Published: 2023

Journal Articles

Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib

Jessica M. Stempel, Rong Wang, Rory Michael Shallis, Scott F. Huntington, Amer M. Zeidan, Natalia Neparidze, Mengyang Di, Xiaomei Ma, Nikolai A. Podoltsev

Blood (2022) 140 (Supplement 1): 11004–11006.

https://doi.org/10.1182/blood-2022-165156

Published: 2022

Journal Articles

Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis

Chen Zhang, Douglas Tremblay, John Magnotti, Lukas Ronner, Nikolai A. Podoltsev, Jason Gotlib, Mark L. Heaney, Andrew Kuykendall, Casey L. O'Connell, Angela G Fleischman, Ruben Mesa, Abdulraheem Yacoub, John Mascarenhas, Jamile M. Shammo

Blood (2022) 140 (Supplement 1): 9693–9695.

https://doi.org/10.1182/blood-2022-157873

Published: 2022

NARROW

Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States

Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

Use of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database

Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia

Educational Impact of Live and Online Enduring CME Activities Presented at the 65 th ASH Annual Meeting on Hematology/Oncology Specialists Evaluated Using Pre-/Post-Education Assessments

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia

Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab

Risk Factors and Predictors of Outcomes after Invasive Fungal Infection Among Patients with Acute Myeloid Leukemia

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

State‐Level Acute Myeloid Leukemia Incidence and Mortality Trends and Association with Obesity in the United States

Feasibility, Safety and Predictors of Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia Discharged “Early” after Intensive Induction Therapy

A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034)

Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United States

The Value and Success of Live Plus Online Enduring CME/CE on Hematology/Oncology Specialists' Ability to Care for Patients with Hematologic Disorders

Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 Trial

Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib

Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only